The Hague, Netherlands:
Experts probing the links between the AstraZeneca coronavirus vaccine and blood clots have found no specific risk factors, including age, but are continuing their research, the European medicines regulator said on Wednesday.
The European Medicines Agency (EMA), however, said its safety committee expected to issue an “updated recommendation” on the controversial vaccine after its monthly meeting next week.
Germany on Tuesday became the latest in a series of countries to advise against using the AstraZeneca jab for young people after rare reports of clotting, although the EMA said it was safe.
“At this time, the review has not identified any specific risk factors, such as age, gender, or a medical history of bleeding disorders, for these very rare events,” said the EMA based in Amsterdam in a press release.
“A causal link with the vaccine is not proven, but it is possible and further analysis is ongoing.”
The EMA statement came after experts gathered on Monday to discuss their latest findings on the AstraZeneca vaccine. Their comments will be discussed at the safety committee meeting next week.
The watchdog reiterated the view it gave in a long-awaited statement on March 18, saying that “its benefits in protecting people from Covid-19 with the associated risks of death and hospitalization. outweigh the possible risks “.
– 62 cases worldwide –
EMA chief Emer Cooke and agency head of pharmacovigilance and epidemiology Peter Arlett told an online press conference the detected cases of rare coagulation – thrombosis of the cerebral venous sinus (CVST) – following AstraZeneca vaccine injections.
They said there were 62 cases of CVST worldwide, including 44 in the European Economic Area (EEA) comprising the European Union and associated states, Norway, Iceland and Liechtenstein.
Cooke added that the EEA figures did not count German cases recorded after March 22, and added that there were 14 deaths in the region “but not all of them were associated with CVST”.
The figures they gave came from 9.2 million AstraZeneca jabs in the EEA region.
Statistics from Brazil, which also uses the AstraZeneca vaccine, were not included.
Cooke said that while “at this point in our investigations the link is possible” between the rare cases of CVST and the AstraZeneca vaccine, further evaluation is needed.
She said the possible CVST adverse reaction ratio “for AZ vaccine based on spontaneous reporting in the EEA, is 4.8 cases per million.”
Compared to the other two Covid vaccines currently being deployed in Europe, she said: “For the BioNTech vaccine based on the same criteria, it was 0.2 cases per million. And for the Moderna vaccine, based on the same criteria, zero cases per million, but that probably reflects that there is much less use of Moderna at the moment in Europe. “
(Except for the title, this story was not edited by UK Time News staff and is posted Platforms.)